Biomarkers Market: Is "Neurological Screening" the 2026...

a adăugat un sunet Health

2026-01-19 09:06:43 -

Biomarkers Market: Is "Neurological Screening" the 2026 Frontier?

A defining 2026 milestone for the industry is the mass adoption of "Neurodegenerative Biomarkers" for the early detection of Alzheimer's and Parkinson's disease. In 2026, the market is identifying "Neurological Indications" as a high-growth segment, with a sustainable CAGR of 10.4% as new blood tests for amyloid-beta and tau proteins become available at local clinics. This 2026 strategy is...

0 Commentarii 0 Distribuiri 34 Views 0 previzualizare